Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BG Medicine and Applied Biosystems have entered into a collaboration agreement in which they will work together to enhance biomarker discovery and development.
Subscribe to our email newsletter
Under the terms of the agreement, BG Medicine will integrate life science technology from Applied Biosystems into its proteomic and metabolomic systems pharmacology workflows and begin to explore applications for Applied Biosystems' genomic tools. The technology will be employed in several strategic initiatives and proprietary programs at BG Medicine over the next two years.
The use of biomarkers offers knowledge about the presence of disease and the role of the biological indicators to improve drug development, early detection of disease, treatment selection and early detection of treatment response.
“With the rapid emergence of molecular medicine and biomarker-guided drug development initiatives, there is an explosive demand for biomarker discovery and validation research as well as the platforms that will deliver these biomarkers to the market,” said Pieter Muntendam, CEO of BG Medicine.
BG Medicine has also validated and implemented Applied Biosystems' proteomic biomarker discovery tools over the past two years. The industrialization of biomarker discovery and validation is a new development that is expected to help advance proteomics, in conjunction with metabolomics and genomics.